NEM® Versus Placebo on Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover In Healthy, Post-Menopausal Women

NCT02751944 | Completed

• 1 other identifier: ESM-CLN#2015T02
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is intended to evaluate the effect of the dietary supplement NEM® brand eggshell membrane versus placebo in reducing exercise-induced joint pain \& stiffness \& cartilage turnover in healthy post-menopausal women. Half of the study participants will receive NEM, once daily, orally while the other half of the study participants will receive placebo, once daily, orally.

Conditions

Exercise-induced Joint Pain Stiffness and Cartilage Turnover

Keywords

exercise-induced; joint pain; joint stiffness; post-menopausal; women; cartilage turnover; CTX-II

Outcome Measures

Primary Outcomes (1)

• Exercise-induced Cartilage Turnover via CTX-II Biomarker

  To evaluate the efficacy of NEM® versus placebo at reducing exercise-induced cartilage turnover in healthy, post-menopausal women by evaluating the change in urinary CTX-II levels.

  2 weeks

Secondary Outcomes (2)

• Exercise-induced Joint Pain via questionnaire

  2 weeks

• Exercise-induced Joint Stiffness via questionnaire

  2 weeks

Study Arms (2)

NEM Treatment

EXPERIMENTAL

NEM, 500 mg, once daily, orally for 2 weeks

Dietary Supplement: NEM

Placebo

PLACEBO COMPARATOR

Placebo, 500 mg, once daily, orally for 2 weeks

Dietary Supplement: Placebo

Interventions

NEM DIETARY_SUPPLEMENT

Dietary supplement for the support of joint health.

Also known as: Natural Eggshell Membrane

NEM Treatment

Placebo DIETARY_SUPPLEMENT

Placebo

Placebo

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must be female, 40-75 years of age.
• Subject must have been amenorrheic (post-menopausal) for at least 12 months prior to baseline evaluation, either naturally or surgically.
• Subject must not have been diagnosed with a joint or connective tissue (JCT) disease (i.e. osteoarthritis, rheumatoid arthritis, spondyloarthritis, bursitis, gout, systemic lupus erythematosus, fibromyalgia, etc.) affecting the hip, knee, or ankle by a licensed physician prior to enrollment evaluation.
• Subjects must have a resting pain/discomfort score of ≤ 3 on the 10 point Likert scale in the knee with the most severe pain/discomfort.
• Subject must be willing and healthy enough to perform moderate exercise.
• Subject must be available for and willing to attend all evaluation visits.
• Subject must be able and willing to give informed consent.
• Subjects must be willing to use only acetaminophen as rescue pain medication, if needed.
• Subjects participating in prior studies evaluating eggshell membrane can participate in the current study so long as they are not currently taking an eggshell membrane supplement and have not done so for 60 days prior to screening.

You may not qualify if:

• Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, tumor necrosis factor (TNF) biologics, etc.), immunosuppressive drugs (i.e. corticosteroids, transplantation medications, etc.).
• Subject has been diagnosed with any clinically significant confounding inflammatory disease or condition that would interfere with the study evaluation, as judged by the clinical investigator (i.e. pseudo gout, Paget's disease, chronic pain syndrome, active rheumatic fever, etc.).
• Subject has a known allergy to eggs or egg products. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.
• a. Such sensitivity may be realized as a reaction to inoculations wherein the inoculate is derived from or contains egg components (i.e., influenza vaccine).
• Subject suffers from clinically significant cardiac, pulmonary, or other complications that would prevent them from performing moderate exercise or could pose a risk to the subject's health, as judged by the clinical investigator.
• Subject participates in activities involving intensive use of the lower extremities (i.e. running / jogging, sports, bicycling, dancing, etc.) 2 or more days per week or participates in activities that involve moderate use of the lower extremities (i.e. walking, golfing, yoga, etc.) 3 or more days per week.
• Subject body weight is greater than 275 pounds (125 kg).
• Subject is currently taking or is unwilling to forgo the use of prescription, over-the-counter (OTC) treatments, and/or dietary supplements affecting joint health within 30 days prior to baseline evaluation and for the duration of the study. Prohibited medications include: NSAIDs, analgesics (other than acetaminophen), opioids, anti-depressants prescribed for painful conditions (i.e. fibromyalgia) \& joint supplements. Examples of these types of medications are: aspirin, ibuprofen, naproxen, oxycodone, propoxyphene, diclofenac, celecoxib, amitriptyline, duloxetine, glucosamine, chondroitin, MSM, white willow bark, turmeric or curcumin, Boswellia, fish oil, etc.
• a. Washout Periods: Subjects are eligible to participate in the study following a 7-day washout period for opioids, a 14-day washout period for analgesics \& NSAIDs, and a 90-day washout period for steroids, anti-depressants, or JCT dietary supplements (i.e. glucosamine, chondroitin, methylsulfonylmethane (MSM), etc.) Acetaminophen must not have been taken within 24 hours of baseline evaluation.
• Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of baseline evaluation.
• Pregnant and breastfeeding women.
• Subject has a history or positive test result of HIV, hepatitis B or hepatitis C.

Sponsors & Collaborators

• ESM Technologies, LLC: lead

Related Publications (1)

• Ruff KJ, Morrison D, Duncan SA, Back M, Aydogan C, Theodosakis J. Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women. Clin Interv Aging. 2018 Feb 19;13:285-295. doi: 10.2147/CIA.S153782. eCollection 2018.

  PMID: 29497287 RESULT

Related Links

• Published in Clinical Interventions in Aging

MeSH Terms

Conditions

Arthralgia

Condition Hierarchy (Ancestors)

Joint Diseases; Musculoskeletal Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Dennis Morrison, D.O.

  QPS-Biokinetic

  PRINCIPAL INVESTIGATOR

• Kevin J Ruff, Ph.D., MBA

  ESM Technologies, LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2016
• First Posted: April 26, 2016
• Study Start: December 1, 2015
• Primary Completion: January 1, 2016
• Study Completion: January 1, 2016
• Last Updated: August 17, 2018

Record last verified: 2018-08

Data Sharing

• IPD Sharing: Will not share